Toll Free: 1-888-928-9744

Genmab A/S - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Genmab A/S - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Genmab A/S - Product Pipeline Review - 2014', provides an overview of the Genmab A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genmab A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Genmab A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Genmab A/S's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Genmab A/S's pipeline products

Reasons to buy

- Evaluate Genmab A/S's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Genmab A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Genmab A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Genmab A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genmab A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Genmab A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Genmab A/S Snapshot 6
Genmab A/S Overview 6
Key Information 6
Key Facts 6
Genmab A/S - Research and Development Overview 7
Key Therapeutic Areas 7
Genmab A/S - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Genmab A/S - Pipeline Products Glance 15
Genmab A/S - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Genmab A/S - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Genmab A/S - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Genmab A/S - Drug Profiles 21
ofatumumab 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
teprotumumab 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
HuMax-TF-ADC 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
DuoBody Cancer-5 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
DuoBody Cancer-6 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DuoBody Undisclosed Program 1 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DuoBody Undisclosed Program 2 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
DuoBody Undisclosed Program 3 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DuoBody Undisclosed Program 4 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Humax Cancer-4 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Humax-Cancer 3 ADC 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HuMax-Her2 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
HuMax-TAC 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
HuMax-TAC-ADC 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Monoclonal Antibody 1 for Central Nervous System Disorders 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Monoclonal Antibody 2 for Central Nervous System Disorders 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Monoclonal Antibody 3 for Central Nervous System Disorders 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TF-011-Monomethyl Auristatin E 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Monoclonal Antibodies for Central Nervous System, Infectious Disease, Oncology and Autoimmune Disorders 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Genmab A/S - Pipeline Analysis 45
Genmab A/S - Pipeline Products by Target 45
Genmab A/S - Pipeline Products by Route of Administration 46
Genmab A/S - Pipeline Products by Molecule Type 47
Genmab A/S - Pipeline Products by Mechanism of Action 48
Genmab A/S - Recent Pipeline Updates 49
Genmab A/S - Dormant Projects 54
Genmab A/S - Discontinued Pipeline Products 55
Discontinued Pipeline Product Profiles 55
HuMax-CD74-ADC 55
ofatumumab 55
RG-1671 55
teprotumumab 56
Genmab A/S - Company Statement 57
Genmab A/S - Locations And Subsidiaries 59
Head Office 59
Other Locations & Subsidiaries 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61
List of Tables
Genmab A/S, Key Information 6
Genmab A/S, Key Facts 6
Genmab A/S - Pipeline by Indication, 2014 9
Genmab A/S - Pipeline by Stage of Development, 2014 11
Genmab A/S - Monotherapy Products in Pipeline, 2014 12
Genmab A/S - Out-Licensed Products in Pipeline, 2014 13
Genmab A/S - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
Genmab A/S - Pre-Registration, 2014 15
Genmab A/S - Phase III, 2014 16
Genmab A/S - Phase II, 2014 17
Genmab A/S - Phase I, 2014 18
Genmab A/S - Preclinical, 2014 19
Genmab A/S - Discovery, 2014 20
Genmab A/S - Pipeline by Target, 2014 45
Genmab A/S - Pipeline by Route of Administration, 2014 46
Genmab A/S - Pipeline by Molecule Type, 2014 47
Genmab A/S - Pipeline Products by Mechanism of Action, 2014 48
Genmab A/S - Recent Pipeline Updates, 2014 49
Genmab A/S - Dormant Developmental Projects,2014 54
Genmab A/S - Discontinued Pipeline Products, 2014 55
Genmab A/S, Subsidiaries 59 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify